94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1498227
Esmolol Improves Sepsis Outcomes Through Cardiovascular and Immune Modulation
Provisionally accepted- 1University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China
- 2Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sepsis poses significant mortality risks. Esmolol, a β1-adrenergic blocker, may improve outcomes through cardiovascular and immune modulation. This study aims to evaluate the effects of Esmolol on survival rates, inflammatory markers, and immune function in sepsis patients.In this retrospective observational study, data from 268 sepsis patients were reviewed, and 125 met the inclusion criteria. These patients were divided into Esmolol and control groups.Data were collected from electronic health records, including survival rates, inflammatory markers (IL-6, PCT), and immune function markers (CD4 + and CD8 + T-cell counts). Statistical analyses included multivariate regression, Kaplan-Meier survival analysis, and Generalized Estimating Equations.Results: The Esmolol group demonstrated significantly higher survival rates at both 14 days (80% vs. 41.67%, p<0.01) and 28 days (75.38% vs. 30.00%, p<0.01) compared to the control group. The median ICU stay was longer in the Esmolol group (12 days vs. 10 days, P=0.045). Significant reductions in heart rate (P=0.002), NE levels (P=0.036), and inflammatory markers were observed in the Esmolol group. Additionally, Esmolol treatment resulted in bidirectional regulation of T-cell counts, increasing CD4 + and CD8 + T-cell counts in patients with higher baseline immune function and decreasing these counts in patients with lower baseline levels (P<0.01).Conclusions: Esmolol improves survival rates and clinical outcomes in sepsis patients, particularly those with higher baseline immune function. The benefits are attributed to early and prolonged administration of Esmolol, highlighting its potential as a valuable addition to sepsis treatment protocols. Future multicenter trials are needed to confirm these findings and refine the use of β1AR in sepsis management.
Keywords: Sepsis, Esmolol, β1-Adrenergic Blocker, Sympathetic Nervous System, Immune Modulation, T-cell regulation
Received: 18 Sep 2024; Accepted: 04 Apr 2025.
Copyright: © 2025 Jing, Xiong, Zhang, Fang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lin Chen, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.